Hostname: page-component-cd9895bd7-dzt6s Total loading time: 0 Render date: 2024-12-28T14:34:23.470Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of oral budesonide in the management of protein-losing enteropathy due to restrictive cardiomyopathy

Published online by Cambridge University Press:  13 September 2013

Hazım A. Gursu ,
Birgul Varan  and
Ilkay Erdogan
Hazım A. Gursu*
Affiliation:
Department of Paediatric Cardiology, Baskent University, Ankara, Turkey
Birgul Varan
Affiliation:
Department of Paediatric Cardiology, Baskent University, Ankara, Turkey
Ilkay Erdogan
Affiliation:
Department of Paediatric Cardiology, Baskent University, Ankara, Turkey
*
Correspondence to. H. A. Gursu, MD, Department of Paediatric Cardiology, Baskent University, Bahcelievler, Cankaya 06490, Ankara, Turkey. Tel: +90 505 5618799; Fax: +90 312 2237333; E-mail: hagursu@yahoo.com.tr
Get access Rights & Permissions [Opens in a new window]

Abstract

A 7-year-old male patient who had abdominal swelling and eyelid oedema was diagnosed with restrictive cardiomyopathy. His serum albumin level was 2.3 g/dl. Protein-losing enteropathy due to restrictive cardiomyopathy was diagnosed and oral budesonide was started. His serum albumin level began to rise and ascites and peripheric oedema disappeared. The patient underwent a successful cardiac transplantation and budesonide was stopped. After the heart transplantation, the albumin level decreased to 2.3 g/dl, and therefore it was restarted. When the serum albumin level increased, the budesonide dose was tapered and stopped in 1 month. Budesonide may be an effective drug in patients with protein-losing enteropathy due to heart failure.

Keywords

Protein-losing enteropathyhypoalbuminaemiacardiac transplantation
Type
Brief Reports
Information
Cardiology in the Young , Volume 24 , Issue 4 , August 2014 , pp. 764 - 766
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Marjet, JAMB, Koert, MD, Merit, MT. Protein-losing enteropathy in children. Eur J Pediatr 2010; 169: 1179–1185.Google Scholar
2. Halaby, H, Bakheet, SM, Shabib, S, et al. Tc-99m human serum albumin scans in children with protein-losing enteropathy. J Nucl Med 2000; 41: 215–219.Google Scholar
3. Sachin, K. The Fontan pathway: what's down the road? Ann Pediatr Cardiol 2008; 1: 83–92.Google Scholar
4. Ostrow, A, Freeze, H, Rychik, C. Protein losing enteropathy after Fontan operation: investigation into possible patophysiologic mechanisms. Ann Thorac Surg 2006; 82: 695–701.CrossRefGoogle Scholar
5. Rychik, J, Piccoli, DA, Barber, G. Usefulness of corticosteroid therapy for protein-losing enteropathy after the Fontan procedure. Am J Cardiol 1991; 68: 819–821.CrossRefGoogle ScholarPubMed
6. Spencer, CM, McTavish, D. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease. Drugs 1995; 50: 854–872.Google Scholar
7. Campieri, M, Ferguson, A, Doe, W, Persson, T, Nilsson, LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997; 41: 209–214.Google Scholar
8. Turner, Z, Lanford, L, Webber, S. Oral budesonide as a therapy for protein-losing enteropathy in patients having undergone Fontan palliation. Congenit Heart Dis 2012; 7: 24–30.Google Scholar
9. Thacker, D, Patel, A, Dodds, K, Goldberg, DJ, Semeao, E, Rychik, J. Use of oral budesonide in the management of protein-losing enteropathy after the Fontan operation. Ann Thorac Surg 2010; 89: 837–842.Google Scholar